Stem Cell Treatment for Myasthenia Gravis

Stem cell treatment for Myasthenia Gravis

Myasthenia Gravis, a chronic autoimmune neuromuscular disease, results in varying degrees of skeletal muscle weakness. The Regeneration Center would like to present an in-depth exploration of the disease, considering its causes, symptoms, diagnosis, and treatments. It further delves into the potential risks and complications, along with the emerging role of stem cell therapy. The aim is to facilitate a comprehensive understanding of living with Myasthenia Gravis or supporting those who are serving to the needs of affected individuals.[1]

Understanding Pathophysiology of Myasthenia Gravis

Myasthenia Gravis, a an often chronic autoimmune neuromuscular disease, is usually characterized by varying degrees of weakness of the body’s skeletal muscles. This neuromuscular disorder results from the immune system mistakenly attacking the body’s tissues, specifically the acetylcholine receptors at the neuromuscular junction, which leads to muscle weakness.

Research indicates that antibodies block, alter, or destroy these receptors, impeding the transmission of nerve signals to the muscles. This autoimmune response is often associated with thymus gland abnormalities, suggesting a potential link between the gland and myasthenia gravis, although the precise relationship remains unclear. The manifestation of this disease varies among patients, with some experiencing localized muscle weakness, such as in the eyes, face, or throat, while others may experience more generalized muscle wasting and symptoms of Osteoarthritis.

The course of myasthenia gravis is often unpredictable, with symptoms sometimes improving spontaneously or following treatment and, at other times, exacerbating without apparent cause. Affected individuals may experience periods of exacerbation and remission, further complicating disease management. Current treatment strategies primarily aim at controlling symptoms and improving quality of life.[2] These include medications to increase the amount of acetylcholine at the neuromuscular junction, immunosuppressants to suppress the production of harmful antibodies, and therapies to remove antibodies from the blood or alter the immune response.Myasthenia Gravis has been known to coexist with other autoimmune conditions such as Sjogren’s syndrome, Hashimoto’s disease, Lyme disease, Diabetes Type 1, Connective Tissue Disorders, SLE Lupus, Fibromyalgia and rheumatoid arthritis.

Understanding the underlying pathophysiology of myasthenia gravis is crucial in developing more effective therapeutic approaches. This knowledge can facilitate the development of targeted therapies, which may lead to improved management of this debilitating neuromuscular disorder.

Causes and Risk Factors of Myasthenia Gravis

Genetic predispositions, infections, and exposure to certain toxic medications have been identified as a potential risk factors for this neuromuscular disorder. Specifically, myasthenia gravis is characterized by the production of autoantibodies against acetylcholine receptors (AChR antibodies) or muscle-specific kinase (anti-MuSK), both crucial elements of the neuromuscular junction.[3]

The immune system, typically a defender against harmful elements, mistakenly identifies these receptors as threats, leading to an autoimmune response. This results in the production of AChR antibodies or anti-MuSK. These antibodies bind to these receptors, blocking or destroying them and impairing communication between nerves and muscles.

Research indicates that approximately 85% of individuals with myasthenia gravis have AChR antibodies, while 7% have anti-MuSK. The remaining individuals typically have other autoantibodies or, in rare cases, no identifiable antibodies. This further suggests the complexity of the disorder and the possible existence of other contributing factors.

Additionally, Thymus gland abnormalities have been associated with this disorder. It is hypothesized that the thymus gland, which plays a vital role in the development of the immune system and can instruct the body to produce these autoantibodies.

Furthermore, environmental factors such as certain infections and medications can trigger or exacerbate myasthenia gravis. These substances may alter the immune system’s function, leading to an autoimmune response against the peripheral nerves and peripheral neuropathy.

Symptoms Associated With Myasthenia Gravis – AChRs

Common symptoms of this neuromuscular disorder includes weakness in the leg and arm muscles, double vision, drooping eyelids, and difficulties with speech, chewing, swallowing, and breathing. These symptoms are often progressive, manifesting subtly before intensifying over time. As a chronic illness, myasthenia gravis necessitates ongoing management to optimize patient outcomes and maintain the highest possible quality of life.

The symptomatic treatment for myasthenia gravis often involves using certain medications, notably corticosteroids, to manage the symptoms and slow the disorder’s progression. The choice of treatment often depends upon the severity and specific symptoms experienced by the patient.

  • Weakness in the arm and leg muscle: This often starts in the hands and feet and progressively affects the entire limb. This might limit the patient’s ability to perform daily tasks.
  • Double vision and drooping eyelids: Visual disturbances are common and can drastically affect the patient’s ability to read, drive, and perform other vision-dependent tasks.
  • Difficulties with speech, chewing, swallowing, and breathing: These impact the patient’s ability to communicate effectively, eat, drink, and breathe comfortably, affecting their overall quality of life.
  • Fatigue and weakness: These symptoms often worsen after periods of activity and can improve after rest, a characteristic feature of autoimmune myasthenia gravis.

A comprehensive understanding of these symptoms, their impact on patient’s quality of life, and the potential treatments available are crucial for those serving patients with this disorder. This knowledge aids in providing empathetic, evidence-based care designed to improve patient outcomes.

How is myasthenia gravis diagnosed?

Diagnosis of this neuromuscular disorder typically involves a comprehensive evaluation, including a thorough clinical history, physical examination, and specific diagnostic tests such as nerve conduction studies and blood tests for specific antibodies. Electrophysiology in the form of nerve conduction studies provides insight into the functionality of the neuromuscular junction, thus aiding in identifying the disorder.

Biological markers, particularly antibodies, are essential in diagnosing myasthenia gravis. Blood tests detect acetylcholine receptor (AChR) antibodies and muscle-specific kinase (MuSK) antibodies. A positive result indicates an abnormal immune response, supporting a diagnosis of myasthenia gravis.

Once a diagnosis is confirmed, treatment strategies, often pharmacotherapy, are implemented to manage the disorder. Commonly used medications include acetylcholinesterase inhibitors, which can increase the availability of of acetylcholine at the neuromuscular junction. Immunosuppression is also a cornerstone of treatment. It reduces the immune response, thereby decreasing the production of harmful antibodies.

To monitor the effectiveness of any treatment, regular re-evaluation is necessary. This often involves repeat clinical examinations, blood tests, and nerve conduction studies. Progress is determined by the reduction in symptom severity, improvements in muscle strength, and decreased levels of specific antibodies in the blood.

Risks and Complications of Myasthenia Gravis

Potential risks and complications associated with this neuromuscular disorder range from mild symptoms such as eye muscle weakness to severe respiratory issues requiring immediate medical attention. These risks and complications of myasthenia gravis can manifest variably across different patients, with some experiencing only mild inconvenience while others suffer from life-threatening challenges.In some rare cases, the cardiovascular system and heart muscles may be targeted by myasthenia gravis (MG). Heart Attacks, Congestive Heart failure, arrhythmia, inflammation of the heart (myocarditis), and chronic can occur when myasthenia gravis affects the heart tissue.

Significant risks associated with myasthenia gravis can include:

  • Myasthenic Crisis: A severe worsening of symptoms, such as respiratory failure, requiring immediate medical intervention.
  • Long-term Effects: Continued weakening of the muscles, tendons and cartilage over time, potentially leading to disability.
  • Treatment Complications: Adverse reactions or side effects to medications and rejection risks
  • Secondary Health Issues: Complications like pneumonia due to swallowing difficulties or osteoporosis due to prolonged steroid use.

The long-term effects of MG can be debilitating. With continued muscular weakness, patients might progressively lose their ability to perform routine tasks, significantly impacting their quality of life. Some patients with MG can also have lower memory performance and symptoms that are misdiagnosed as Alzheimer’s, multiple sclerosis & Parkinson’s.Myasthenia gravis has also found to be associated with Crohn’s disease (CD) & ulcerative colitis (UC).

Can myasthenia gravis cause lung problems?

In some cases Myasthenia gravis can directly affect the respiratory system, causing severe respiratory muscle weakness, abnormal breathing patterns, and blunted ventilatory responses similar to those with lung diseases. A MG crisis is diagnosed when a patient needs ventilatory support due to weakness of respiratory muscles. This event occurs in about 15% all patients diagnosed with MG at least once in their lifetime.

 Treatment Options for Myasthenia Gravis

Treatment options for this neuromuscular disorder encompass a variety of approaches, including medication, surgery, and physical therapy, all aimed at managing symptoms and improving the patient’s quality of life. Recent scientific advancements have also led to the development of stem cell treatment for myasthenia gravis.This innovative new treatment modality works on the cellular level and can use autologous or allogenic stem cells to replace damaged neuromuscular cells.

The efficacy of stem cells for myasthenia gravis treatment is under extensive investigation, with results from preliminary clinical trials showing promising outcomes. The regenerative potential of isolated stem cell therapy has been demonstrated, providing hope for a therapeutic option that could reverse the damage caused by the disorder rather than merely managing the symptoms.

Surgery, specifically thymectomy, is another crucial treatment approach for this disorder. It involves the removal of the thymus gland, which often exhibits abnormalities in individuals with myasthenia gravis. Research published in clinical trials have revealed that patients who underwent thymectomy experienced fewer myasthenia gravis crises and required lower doses of medication, thereby improving their quality of life.

While the goal is to treat myasthenia gravis with stem cells and other novel approaches, it is essential to recognize the importance of comprehensive, multidisciplinary care for these patients. This includes physical therapy to manage muscle weakness and other symptoms alongside medical and surgical interventions. As research progresses, more effective and less invasive treatment options will become available, offering new hope for individuals affected by this challenging disorder.

Stem cell Therapy for Myasthenia Gravis

The treatment of myasthenia gravis with stem cells has emerged as a promising technique. However, its application has challenges. The primary concern for some are in the risk of rejection of transplanted allogeneic stem cells by the patient’s immune system, which can lead to severe complications.

Due to its regenerative capabilities, stem cell therapy has emerged as a effective therapeutic intervention for this debilitating neuromuscular disorder. Myasthenia gravis disease is characterized by muscle weakness and fatigue, has traditionally been managed with immunosuppressive drugs and thymectomy. However, the potential of stem cell therapy for myasthenia gravis is being increasingly recognized, driven by advances in the understanding of mesenchymal stem cells and pluripotent stem cells.[4]

Isolated Mesenchymal stem cells, in particular, have been found to possess immunomodulation properties, enabling them to modify the immune system’s response. These cells can potentially suppress the production of autoantibodies that block neuromuscular transmission in myasthenia gravis, thus alleviating symptoms of the disorder.

  • Multipotent stem cells have the ability to differentiate into any cell type in the body, including muscle cells. This offers the potential for replacing damaged muscle cells in myasthenia gravis.
  • Isolated  Umbilical Cord Mesenchymal stem cells can modulate the immune system and suppress the production of harmful autoantibodies.
  • Stem cell therapy can address the root cause of the disease and not just manage the symptoms.
  • The therapeutic applications of stem cells extend beyond myasthenia gravis, with potential benefits for other common autoimmune diseases and neurological disorders.

The potential of stem cell therapy for myasthenia gravis is an exciting area of research. However, it is still in its early stages, and further rigorous, well-designed studies are needed to fully understand the efficacy, safety, and optimal application of this novel therapeutic approach.

Play Video about comparison-mesenchymal-stemcell-sources-viability-potency-regen

Living with myasthenia gravis

Living with this neuromuscular disorder presents unique challenges and adjustments due to muscle weakness and fatigue, necessitating a comprehensive management plan that includes pharmacological interventions, lifestyle modifications, and supportive care. The disorder, characterized by interrupted communication between nerves and muscles at cholinergic synapses, demands a multi-pronged treatment approach.

Given its potential to regulate inflammatory mediators implicated in the disorder’s pathology stem cell therapy can halt or slow down myasthenia gravis progression by modulating the immune response and promoting tolerance induction. However, safety and efficacy remain paramount despite its promise, necessitating further research and rigorous clinical trials.[5]

Pharmacological interventions aim to improve neuromuscular transmission, mitigate symptoms, and manage complications. These include cholinesterase inhibitors, immunosuppressants, and corticosteroids. However, their use has side effects, underscoring the need for regular monitoring and dosage adjustment.

Lifestyle modifications are equally crucial in managing this disorder. Regular exercise, balanced nutrition, and adequate rest can significantly improve the quality of life of affected individuals. Rehab services, including physiotherapy and occupational therapy, can also help manage muscle weakness and fatigue.

Supportive care, including psychological support, is integral to the management plan. The chronic nature of the disorder, along with its fluctuating course, can lead to significant psychological distress. Therefore, regular psychological assessments and interventions are recommended.

Myasthenia Gravis is a neuromuscular disorder with various causes and risk factors, including genetics and environmental influences. The disease manifests through various symptoms, with diagnosis often requiring multiple tests. Despite potential complications, several treatment options exist, with stem cell therapy emerging as the most promising approach. As stem cell research progresses, a better understanding and more effective treatments are expected to help improve the quality of life for those living diagnosed with Myasthenia Gravis.

Published Clinical Citations

[1] ^Tiamkao S, Pranboon S, Thepsuthammarat K, Sawanyawisuth K. Prevalence of factors associated with poor outcomes of hospitalized myasthenia gravis patients in Thailand. Neurosciences (Thailand). 2014 Oct;19(4):286-90. PMID: 25274587; PMCID: PMC4727666.

[2] ^ Tannemaat MR, Verschuuren JJGM. Emerging therapies for autoimmune myasthenia gravis: Towards treatment without corticosteroids. Neuromuscul Disord. 2020 Feb;30(2):111-119. doi: 10.1016/j.nmd.2019.12.003. Epub 2019 Dec 14. PMID: 32007304.

[3] ^Sanders DB, Wolfe GI, Narayanaswami P; MGFA Task Force on MG Treatment Guidance. Developing treatment guidelines for myasthenia gravis. Ann N Y Acad Sci. 2018 Jan;1412(1):95-101. doi: 10.1111/nyas.13537. PMID: 29381223.

[4] ^ Sudres M, Maurer M, Robinet M, Bismuth J, Truffault F, Girard D, Dragin N, Attia M, Fadel E, Santelmo N, Sicsic C, Brenner T, Berrih-Aknin S. Preconditioned mesenchymal stem cells treat myasthenia gravis in a humanized preclinical model. JCI Insight. 2017 Apr 6;2(7):e89665. doi: 10.1172/jci.insight.89665. PMID: 28405609; PMCID: PMC5374074.

[5] ^Beland B, Hahn C, Jamani K, Chhibber S, White C, Atkins H, Storek J. Autologous hematopoietic stem cell transplant for the treatment of refractory myasthenia gravis with anti-muscle specific kinase antibodies. Muscle Nerve. 2023 Feb;67(2):154-157. doi: 10.1002/mus.27772. Epub 2022 Dec 26. PMID: 36527328.

Page last updated on 11 January 2024 | Topic last reviewed: 15 June 2023